Nov 1, 2022 · AZP-3601 is a long-acting PTH/PTHrP (1-36) analog currently being investigated as a potential treatment option for HP. As compared to conventional PTH1-34, AZP-3601 binds …

Apr 10, 2025 · The objective of this study was to assess the long-term safety and efficacy of palopegteriparatide in patients with hypoparathyroidism. Palopegteriparatide is a parathyroid …

Parathyroid hormone (PTH) analogs with improved actions in vivo could lead to optimized treatments for bone and mineral ion diseases. Rapid clearance from the circulation and short …

May 21, 2025 · Patients treated with the parathyroid hormone analog continues to show improved renal function and skeletal dynamics at 2 years, with no new safety signals.

Mar 17, 2025 · Abstract Context: Conventional therapy for hypoparathyroidism aims to alleviate symptoms of hypocalcemia but does not address insufficient parathyroid hormone (PTH) …

TransCon™ PTH is a prodrug of parathyroid hormone (PTH) designed to restore physiologic levels of PTH 24 hours a day. By doing so, we believe TransCon PTH can address both the …

ORLANDO -- Palopegteriparatide (Yorvipath) led to sustained improvements over 2 years in adults with chronic hypoparathyroidism, according to long-term phase III PaTHway trial results.

May 14, 2025 · Subject of Research: Prolongation of parathyroid hormone analog activity via peptide lipidation for enhanced therapeutic efficacy in bone metabolism disorders Article Title: …

Aug 13, 2024 · Yorvipath (palopegteriparatide) is a long-acting parathyroid hormone analog that releases PTH (1-34) throughout the day, which temporarily restores physiologic levels of …

Jan 26, 2023 · In contrast, parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP) analogs belong to a different class of osteoporosis drugs called "anabolic" agents …